Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity

Patrick R. Hagner, Hsiling Chiu, Maria Ortiz, Benedetta Apollonio, Maria Wang, Suzana Couto, Michelle F. Waldman, Erin Flynt, Alan G. Ramsay, Matthew Trotter, Anita K. Gandhi, Rajesh Chopra, Anjan Thakurta

    Research output: Contribution to journalArticlepeer-review

    40 Citations (Scopus)
    279 Downloads (Pure)


    Lenalidomide is an immunomodulatory agent that has demonstrated clinical benefit for patients with relapsed or refractory mantle cell lymphoma (MCL); however, despite this observed clinical activity, the mechanism of action (MOA) of lenalidomide has not been characterized in this setting. We investigated the MOA of lenalidomide in clinical samples from patients enrolled in the CC-5013-MCL-002 trial (NCT00875667) comparing single-agent lenalidomide versus investigator's choice single-agent therapy and validated our findings in pre-clinical models of MCL. Our results revealed a significant increase in natural killer (NK) cells relative to total lymphocytes in lenalidomide responders compared to non-responders that was associated with a trend towards prolonged progression-free survival and overall survival. Clinical response to lenalidomide was independent of baseline tumour microenvironment expression of its molecular target, cereblon, as well as genetic mutations reported to impact clinical response to the Bruton tyrosine kinase inhibitor ibrutinib. Preclinical experiments revealed lenalidomide enhanced NK cell-mediated cytotoxicity against MCL cells via increased lytic immunological synapse formation and secretion of granzyme B. In contrast, lenalidomide exhibited minimal direct cytotoxic effects against MCL cells. Taken together, these data provide the first insight into the clinical activity of lenalidomide against MCL, revealing a predominately immune-mediated MOA.
    Original languageEnglish
    Pages (from-to)399-409
    JournalBritish Journal of Haematology
    Issue number3
    Early online date2 Aug 2017
    Publication statusPublished - Nov 2017


    Dive into the research topics of 'Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity'. Together they form a unique fingerprint.

    Cite this